key: cord-0822745-8yeo99i3 authors: Mazzitelli, Maria; Serapide, Francesca; Tassone, Bruno; Laganà, Domenico; Trecarichi, Enrico Maria; Torti, Carlo title: Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation date: 2020-07-01 journal: Mediterr J Hematol Infect Dis DOI: 10.4084/mjhid.2020.054 sha: 10d27136d500ca63d10ca0f541a03982921f5815 doc_id: 822745 cord_uid: 8yeo99i3 nan 74-year-old male suffering from Parkinson disease, lung fibrosis, and hypertension was admitted to the emergency department for acute respiratory failure on April 17 th , 2020, and tested positive for SARS-CoV-2. He was diagnosed with paroxysmal atrial fibrillation (CHA 2 DS 2 -VASC score=3) and was prescribed LMWH (4000 UI, subcutaneously twice daily). Padua score was 5. HAS-BLED score was 2. He was transferred of care to our unit on April 18 th , 2020, where oxygen support was prescribed with high flow nasal cannula (HFNC) 40% FiO 2 40 liters/minute. The patient reported an accidental fall, without apparent consequences on April 18 th , with CT scan results not showing anything significant, but for lung disease. Coagulation parameters at the admission were: D-dimer 0.30 mg/l (normal values 0-0.55 mg/l), fibrinogen 216 mg/dl (normal values 200-400 mg/dL), PT 64% (normal values 70-120%), PTT 33 seconds (normal values 22-36.6 seconds), and INR 1.40. SIC score was 4. After one week he rapidly developed hypotension (blood pressure 85/45 mmHg) and severe anaemia (haemoglobin levels decreased from 13.1 to 6.9 g/dl) over three days. Coagulation parameters were: D-dimer 0.39 mg/l (normal values 0-0.55 mg/l), fibrinogen 135 mg/dl (normal values 200-400 mg/dL), PT 49% (normal values 70-120%), PTT 43 seconds (normal values 22-36.6 seconds), and INR 1.62. SIC score remained 4. He underwent a CT scan, which showed massive serum-blood collection (10 cm diameter) displacing the left kidney and hematoma with ongoing bleeding in the ipsilateral psoas muscle (see Figure 1 , panel A). He received several blood and plasma transfusions and supportive care immediately, but unfortunately, he died after two days (April 28 th ). For worsening of clinical conditions, the patient was admitted to our unit for COVID-19 pneumonia on April 2 nd , 2020. Venturi mask (SpO2 60% 15 l/min) was applied. Soon after admission, she was diagnosed with paroxysmal atrial fibrillation (CHA 2 DS 2 -VASC score=5), so LMWH (4000 UI, subcutaneously twice daily) was prescribed. Coagulation parameters at the admission were: D-dimer 1. CT scan showed a large hematoma with imbued and non-homogeneous appearance of the adductor muscles of the right thigh (see Figure 1, panel B) . The patient received blood transfusions immediately. Anticoagulation was stopped for one day; then she was switched to fondaparinux 2.5 mg/daily (due to the thrombocytopenia). Case #3. A 56-year-old male with sequelae of stroke and meningoencephalitis, diabetes, hyperthyroidism, chronic kidney disease, non-alcoholic fatty liver disease, and hypertension was admitted on April, 1 rst with persistent fever and shortness of breath, requiring Venturi mask (SpO2 60% 15 l/min). He was diagnosed with paroxysmal atrial fibrillation (CHADS2-VASC2=5) and was prescribed LMWH (4000 UI, subcutaneously twice daily). Coagulation parameters at the admission were: D-dimer 1. CT scan showed hematoma in the right psoas muscle with non-homogeneity of adjacent tissues and small liquid effusion among the intestinal loops (see Figure 1 , panel C). He received several blood and plasma transfusions and supportive care immediately, with a good clinical outcome. Anticoagulation was stopped for two days, and then fondaparinux was started, due to occurring thrombocytopenia. Our work highlights haemorrhage as an overlooked possible risk in patients with COVID-19 on anticoagulant treatment. In the study patients, we prescribed LMWH for three reasons: i) several guidelines suggest prescription of LMWH for any patients with COVID-19 to prevent thromboembolic events; 6,7 ii) SIC score was above the cut-off suggested for the prescription of anticoagulant therapy in our patients, 13 and iii) patients suffered from paroxysmal atrial fibrillation. 12 The last reason led us to prescribe LMWH at therapeutical dosage. So, we could not exclude that, in patients with COVID-19, such a high dosage could have contributed to increasing the risk of bleeding. Unfortunately, although validated scores are available to weight possible contraindications of anticoagulants (i.e., risk of bleedings) 10 against the indication for it, such scores are not validated explicitly in COVID-19 patients. This validation process would be necessary because SARS-CoV-2 is not only able to interfere with the coagulation cascade in a prothrombotic way 14 , but it can also induce a sepsis-like syndrome, including disseminated intravascular coagulation, of which haemorrhage can be an outcome. 2 So, a careful evaluation of the relative risk of thrombosis and bleeding should be required in these patients. Importantly, it seems that existing scores [10] [11] [12] were not conclusive in balancing the indication to use anticoagulants with the risk of bleeding in our patients. In fact, while according to Padua, CHA 2 DS 2 -VASC, and SIC scores anticoagulants were recommended, HAS-BLED indicated a moderate risk of bleeding in all cases presented in this paper. Given these considerations, clinicians could decide to reduce dosage of heparin; however, no data are supporting this choice. By contrast, several data have shown that heparin should be prescribed in order to prevent COVID-19 associated coagulopathy, 6 suggesting that the risk of bleeding is less hazardous. In conclusion, our experience showed that lifethreatening major bleedings can occur during anticoagulation treatment and that a careful clinical and laboratory monitoring of such patients with COVID-19 is required. This proactive approach is essential especially in people who have an increased risk of bleedings, i.e., elderly, although validated scores may indicate that this risk is only moderate. In other terms, scores to evaluate the risk of bleeding may need to be validated explicitly in patients with COVID-19. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past ISTH interim guidance on recognition and management of coagulopathy in COVID-19 Lombardy Section of the Italian Society of Infectious and Tropical Diseases. Vademecum for the treatment of people with COVID-19 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey A risk assessment model for the identification of hospitalised medical patients at risk for venous thromboembolism: The Padua Prediction Score Impact of the CHA 2DS 2-VASc score on anticoagulation recommendations for atrial fibrillation New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis We want to thank all our patients and our nurses. We also thank the Infectious Diseases and Tropical Medicine (IDTM) of the University